GeoVax Lab CEO to Speak at Tribe Public Webinar
![GeoVax Lab CEO to Speak at Tribe Public Webinar](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Registration Open for Tribe Public’s Webinar Featuring GeoVax Lab’s CEO
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention
Event Overview
GeoVax Lab, Inc. (NASDAQ: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, has announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public’s Webinar Presentation and Q&A Event titled "Now Is Not the Time to Monkey(pox) Around." The event is set to occur at 8:00am PT / 11:00am ET on the upcoming Friday.
Webinar Participation
Participants can register for the complimentary event and forward their questions for the CEO to Tribe Public or share them via the ZOOM chat feature during the event. Tribe Public’s Managing Member will host the event and provide a platform for all inquiries.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology firm focused on developing innovative vaccines for infectious diseases and therapies for solid tumor cancers. The company’s lead program is GEO-CM04S1, a next-generation COVID-19 vaccine. This program was recently awarded a significant contract to sponsor a large-scale Phase 2b clinical trial aimed at evaluating the efficacy of GEO-CM04S1 against an approved COVID-19 vaccine. Currently, GEO-CM04S1 is involved in three Phase 2 clinical trials targeting various patient demographics.
Innovative Cancer Therapies
In oncology, GeoVax is evaluating a cutting-edge oncolytic solid tumor gene-directed therapy in a multicenter clinical trial for advanced cancers. The company boasts a robust IP portfolio supporting its technologies and products, holding worldwide rights as it moves forward in its mission.
Contact Information
Company Contact: info@geovax.com | 678-384-7220
Investor Relations Contact: austin.murtagh@precisionaq.com | 212-698-8696
Media Contact: sr@roberts-communications.com | 202-779-0929
Frequently Asked Questions
What is the purpose of the upcoming webinar?
The webinar aims to provide an overview of Mpox, its rapid spread, and methods for control, treatment, and prevention.
Who will be presenting at the webinar?
David Dodd, the CEO of GeoVax Labs, will be presenting during the event.
How can I register for the webinar?
Interested participants can register for the complimentary event on the Tribe Public website.
What is GeoVax Labs known for?
GeoVax Labs is recognized for its development of immunotherapies and vaccines for cancers and infectious diseases, including innovative approaches to COVID-19.
What are the company’s clinical trial focus areas?
GeoVax focuses on vaccine development for infectious diseases and therapies for solid tumor cancers, including leading clinical trials for its COVID-19 vaccine.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Canadian Premium Sand Inc. Extends Warrants Expiry Date
- Marksmen Energy Completes Successful Private Placement
- Skye Bioscience Grants Stocks Options Under Incentive Plan
- Lincoln Educational Services to Showcase Growth at Conference
- Catalyst Accelerator Ogden Launches Fall 2024 Cohort
- Millicom Confirms Expiration of Consent Solicitation
- IMAC Holdings Addresses Nasdaq Compliance Notification
- Cellectar Announces Restatement of Financial Statements
- Cingulate Inc. Adjourns Special Meeting to Enhance Stockholder Voting
- ARCA biopharma Implements Reverse Stock Split Ahead of Merger